Prostate cancer screening is one of the most controversial topics in urology. On one hand, there is randomized data showing that PSA screening results in earlier stages at diagnosis, improved oncologic outcomes after treatment, and lower prostate cancer mortality rates. However, the downsides include unnecessary biopsies due to false positive PSA tests, overdiagnosis of some insignificant cancers, and potential side effects from prostate biopsy and/or prostate cancer treatment. The ongoing controversy is highlighted by the divergent recommendations on screening from multiple professional organizations. The purpose of this article is to summarize the recent guidelines on prostate cancer screening from 2012 to present.
Written by:
Loeb S. Are you the author?
Department of Urology and Population Health, New York University, NY.
Reference: BJU Int. 2014 Jul 1. Epub ahead of print.
doi: 10.1111/bju.12854
PubMed Abstract
PMID: 24981126
UroToday.com Prostate Cancer Section
